Eli Lilly and Co (LLY) : New York State Common Retirement Fund scooped up 169,331 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 3,056,239 shares of Eli Lilly and Co which is valued at $245,171,493.Eli Lilly and Co makes up approximately 0.34% of New York State Common Retirement Fund’s portfolio.
Other Hedge Funds, Including , Massmutual Trust Co Fsbadv reduced its stake in LLY by selling 172 shares or 25.11% in the most recent quarter. The Hedge Fund company now holds 513 shares of LLY which is valued at $41,153. Vestor Capital added LLY to its portfolio by purchasing 535 company shares during the most recent quarter which is valued at $43,656. Eli Lilly and Co makes up approx 0.01% of Vestor Capital’s portfolio. Sequoia Financial Advisors added LLY to its portfolio by purchasing 2,554 company shares during the most recent quarter which is valued at $211,701. Eli Lilly and Co makes up approx 0.06% of Sequoia Financial Advisors’s portfolio. Cg Asset Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 4,089 shares of LLY which is valued $341,023.Oakbrook Investments boosted its stake in LLY in the latest quarter, The investment management firm added 5,100 additional shares and now holds a total of 103,630 shares of Eli Lilly and Co which is valued at $8,455,172. Eli Lilly and Co makes up approx 0.45% of Oakbrook Investments’s portfolio.
Eli Lilly and Co closed down -0.72 points or -0.90% at $79.06 with 37,46,012 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $78.78 and an intraday high of $79.79 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.